1. Home
  2. UTHR vs TLK Comparison

UTHR vs TLK Comparison

Compare UTHR & TLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • TLK
  • Stock Information
  • Founded
  • UTHR 1996
  • TLK 1884
  • Country
  • UTHR United States
  • TLK Indonesia
  • Employees
  • UTHR N/A
  • TLK N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • TLK Telecommunications Equipment
  • Sector
  • UTHR Health Care
  • TLK Telecommunications
  • Exchange
  • UTHR Nasdaq
  • TLK Nasdaq
  • Market Cap
  • UTHR 13.8B
  • TLK 16.1B
  • IPO Year
  • UTHR 1999
  • TLK 1995
  • Fundamental
  • Price
  • UTHR $408.38
  • TLK $19.57
  • Analyst Decision
  • UTHR Strong Buy
  • TLK
  • Analyst Count
  • UTHR 15
  • TLK 0
  • Target Price
  • UTHR $449.13
  • TLK N/A
  • AVG Volume (30 Days)
  • UTHR 884.7K
  • TLK 577.4K
  • Earning Date
  • UTHR 10-29-2025
  • TLK 10-29-2025
  • Dividend Yield
  • UTHR N/A
  • TLK 5.26%
  • EPS Growth
  • UTHR 17.94
  • TLK N/A
  • EPS
  • UTHR 25.63
  • TLK 0.01
  • Revenue
  • UTHR $3,077,800,000.00
  • TLK $9,097,469,437.00
  • Revenue This Year
  • UTHR $13.89
  • TLK $1.88
  • Revenue Next Year
  • UTHR $5.68
  • TLK $3.04
  • P/E Ratio
  • UTHR $15.74
  • TLK $14.27
  • Revenue Growth
  • UTHR 17.62
  • TLK N/A
  • 52 Week Low
  • UTHR $266.98
  • TLK $13.15
  • 52 Week High
  • UTHR $436.95
  • TLK $21.00
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 70.49
  • TLK 54.75
  • Support Level
  • UTHR $396.12
  • TLK $18.88
  • Resistance Level
  • UTHR $407.06
  • TLK $20.27
  • Average True Range (ATR)
  • UTHR 13.55
  • TLK 0.24
  • MACD
  • UTHR 1.60
  • TLK -0.01
  • Stochastic Oscillator
  • UTHR 79.59
  • TLK 57.45

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About TLK PT Telekomunikasi Indonesia Tbk

PT Telkom Indonesia (Persero) Tbk is the integrated telecommunications provider in Indonesia. The company is focusing on dividing business into 3 Digital Business Domains namely, digital connectivity, digital platform, and digital services. It also provides a wide range of other communication services, including telephone network, interconnection services, multimedia, data and internet communication-related services, satellite transponder leasing, leased line, intelligent network and related services, cable television, and VoIP services. The group derives revenue from product lines: Mobile, Consumer, Enterprise, WIB and Others.

Share on Social Networks: